

Results of Annual General Meeting

Melbourne, Australia; 24 November 2020: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), advises that its Annual General Meeting of Shareholders was held today at 11.30 am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata has advanced its Cymerus MSC products into a Phase 2 trial for severe complications arising from COVID-19 and a Phase 3 trial for osteoarthritis. A Phase 2 trial in critical limb ischemia has received regulatory approval and a Phase 2 trial in GvHD is planned by licensee Fujifilm. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack, sepsis, acute respiratory distress syndrome (ARDS) cytokine release syndrome and pulmonary fibrosis.

Disclosure of Proxy Votes

Cynata Therapeutics Limited

Annual General Meeting

Tuesday, 24 November 2020



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
01 Adoption of Remuneration Report	P	39,615,383	31,361,611 79.17%	6,699,961 16.91%	285,275	1,553,811 3.92%	32,915,422 83.09%	6,699,961 16.91%	285,275
02 Re-election of Dr Stewart Washer as a Director	P	43,852,657	35,995,339 82.08%	6,302,507 14.37%	419,907	1,554,811 3.55%	37,550,150 85.63%	6,302,507 14.37%	419,907
03 Re-election of Dr Darryl Maher as a Director	P	44,224,934	41,106,743 92.95%	1,563,380 3.54%	47,630	1,554,811 3.52%	42,661,554 96.46%	1,563,380 3.54%	47,630
04 Ratification of issue of Shares under Placement – Listing Rule 7.1 capacity	P	33,662,865	25,866,468 76.84%	6,090,620 18.09%	244,141	1,705,777 5.07%	27,572,245 81.91%	6,090,620 18.09%	244,141
05 Approval of 10% Placement Facility	P	43,915,089	36,374,055 82.83%	5,962,231 13.58%	357,475	1,578,803 3.60%	37,952,858 86.42%	5,962,231 13.58%	357,475
06 Replacement of the Company's Constitution	P	43,798,488	36,916,038 84.29%	4,741,673 10.83%	474,076	2,140,777 4.89%	39,056,815 89.17%	4,741,673 10.83%	474,076
07 Approval of issue of Incentive Options to Dr Geoff Brooke	P	39,467,912	31,876,855 80.77%	6,819,509 17.28%	91,971	771,548 1.95%	32,648,403 82.72%	6,819,509 17.28%	91,971



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
08 Approval of issue of Incentive Options to Dr Ross Macdonald	P	39,556,253	29,940,747 75.69%	8,838,958 22.35%	3,630	776,548 1.96%	30,717,295 77.65%	8,838,958 22.35%	3,630
09 Approval of issue of Incentive Options to Dr Darryl Maher	P	39,474,135	32,329,277 81.90%	5,568,310 14.11%	85,748	1,576,548 3.99%	33,905,825 85.89%	5,568,310 14.11%	85,748
10 Approval of issue of Incentive Options to Dr Stewart Washer	P	39,555,030	29,138,636 73.67%	8,746,846 22.11%	209,709	1,669,548 4.22%	30,808,184 77.89%	8,746,846 22.11%	209,709
11 Approval of issue of Incentive Options to Dr Paul Wotton	P	39,555,030	28,526,097 72.12%	9,452,385 23.90%	4,853	1,576,548 3.99%	30,102,645 76.10%	9,452,385 23.90%	4,853
12 Approval of issue of Incentive Options to Peter Webse	P	39,260,643	29,139,524 74.22%	8,544,571 21.76%	299,240	1,576,548 4.02%	30,716,072 78.24%	8,544,571 21.76%	299,240

